News

Glumetza 1,000mg will be introduced to health-care professionals throughout the country by Biovail Pharmaceuticals Canada (BPC), the company’s Canadian sales and marketing division. Scott Smith, vice-president and general

The new alliance will focus on identifying neurobiological differences between cancer patients who develop chemotherapy-induced pain and patients who experience little or no pain. Scientists at M D

The public offering price of $9 per share results in net proceeds to Seattle Genetics of approximately $97.5 million, after deducting underwriting discounts and commissions and offering expenses.

Grant Carlson, Calgenex president & CEO, said: “The move to the public marketplace has always been in our long term plans. The increased access to capital, as well

Under this M-CRADA, NCI will assess Serenex’s novel, small molecule, orally bioavailable Hsp90 inhibitor SNX-5422 as a potential therapeutic for non-small cell lung cancer. Richard Kent, president and

Preliminary studies were conducted at Chulalongkorn University in Bangkok, Thailand, one of a few labs in Asia used by the US Centers of Disease Control (CDC) to conduct

Under the terms of the agreement, Samaritan will grant CHDI an 18-month non-exclusive license to evaluate the usefulness of six of Samaritan’s Alzheimer’s drugs, SP-233, Sp-sc4, Sp-sc7, Sp-04,

The marketing authorization application (MAA) for Thalidomide Pharmion was submitted to the European Medicines Agency (EMEA) in January 2007. The EMEA’s Committee for Medicinal Products for Human Use

PharmatrophiX is developing a series of small molecule compounds called ‘neurotrophin mimetics’ that mimic the function of neurotrophins. These mimetics are the most promising compounds to date that